Streetbeat News

Stock Prices

CROX

Crocs has lowered its FY23 outlook, now expecting revenue of $3.905B-$3.94B, down from the previous estimate of $4.00B-$4.06B. The adjusted EPS is now expected to be $11.55-$11.85, down from the prior $11.83-$12.22. The company also expects an adjusted operating margin of approximately 27%. The revenue growth for the Crocs brand is expected to be 12%-13%, while the HEYDUDE brand is expected to grow 4%-6%. Capital expenditures are expected to be approximately $125-$135 million.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:53 am

SBUX

During a conference call, a Starbucks executive stated that the company expects its global comparable growth to be between 5% and 7% for the fiscal year 2024.

Portfolio Pulse from Charles Gross

November 02, 2023 | 11:52 am

ITCI

Intra-Cellular Therapies has increased its 2023 net product sales guidance for CAPLYTA from $445M-$465M to $460M-$470M.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:51 am

BR

Broadridge Financial Solutions has reiterated its FY24 financial guidance, maintaining its recurring revenue growth constant currency at 6%-9% and adjusted EPS growth at 8%-12%. The estimates are in line with the market expectations of $6.53B and $7.64 respectively.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:49 am

SBUX

Starbucks' executive reported during a conference call that the company's average weekly sales in China grew quarter over quarter, in line with their guidance of low to mid single digit growth.

Portfolio Pulse from Charles Gross

November 02, 2023 | 11:49 am

UPBD

Upbound Group has revised its FY23 guidance for revenue to $3.95B - $4.00B, up from the previous range of $3.90B-$4.00B. The company also adjusted its EPS to $3.45 – $3.55 from $3.25 - $3.55. The new estimates are higher than the market expectation of $3.93B revenue and $3.44 EPS.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:48 am

CROX

Crocs Inc. has projected its 4Q23 revenue to be between $903M-$938M, lower than the consensus estimate of $1.02B. The company also expects its adjusted EPS to be between $2.05-$2.35, which is below the consensus of $2.77. The adjusted operating margin is expected to be around 21%.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:48 am

RACE

Ferrari has reported its quarterly net revenues of €1,544M, marking a 24% increase. The company's adjusted EPS also rose by 48% to €1.82.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:48 am

ACXP

Acurx Pharmaceuticals announced top-line results from Phase 2 trials of Ibezapolstat, showing a 96% clinical cure rate in patients with C. difficile infection. The drug was well tolerated with no serious adverse events reported. Further analyses are forthcoming, and preparations are underway for an End-of-Phase 2 FDA meeting and advancement to Phase 3. Despite the positive results, Acurx's shares experienced a selloff.

Portfolio Pulse from Charles Gross

November 02, 2023 | 11:45 am

UPBD

Upbound Group (NASDAQ:UPBD) reported Q3 adjusted earnings of $0.79 per share, beating the analyst consensus estimate of $0.75 by 5.33%. However, this is a 15.96% decrease from the same period last year. The company also reported quarterly sales of $979.10 million, beating the estimate of $968.56 million by 1.09%, but this is a 4.38% decrease from last year.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:45 am